| Market Cap | $1.02B+79.3% |
| Revenue (ttm) | n/a |
| Net Income | -$95.18M |
| EPS | -$2.32 |
| Shares Out | 40.11M |
| PE Ratio | n/a |
| Forward PE | -8.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 522,526 |
| Open | $25.76 |
| Previous Close | $26.51 |
| Day's Range | $24.40 - $26.48 |
| 52-Week Range | $12.51 - $37.48 |
| Beta | 1.45 |
| Analysts | Strong Buy |
| Price Target | $38.67(+52.41%) |
| Earnings Date | Nov 10, 2026 |
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating ANRO in the last 3 months, one vote each. Issuer-paid research is not counted.
$ANRO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ANRO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ANRO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ANRO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ANRO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ANRO from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ANRO’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrade to Buy, positive price targets, and upcoming clinical catalysts outweigh insider selling and valuation concerns.
Recent Insider Activity
Insider Score Trend Over Time
-22.0 since Oct 2Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| PSIL | AdvisorShares Psychedelics ETF | 5.15% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 1.73% |
| IBRN | iShares Neuroscience and Healthcare ETF | 1.60% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.48% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 1.27% |
| BBC | Virtus Biotech Clinical Trials ETF | 1.07% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.79% |
| TDNA | T. Rowe Price Biotech ETF | 0.40% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.26% |
| IWC | iShares Micro-Cap ETF | 0.25% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.21% |
| OPTZ | Optimize Strategy Index ETF | 0.16% |
Weight is the stock’s share of each fund’s holdings.
